Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease

Background: Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson’s disease (PD) and GSH augmentation has been proposed as a therapeutic strategy in PD. Objective: This Phase IIb study was designed to evaluate whether a Phase III study of intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mischley, Laurie K., Lau, Richard C., Shankland, Eric G., Wilbur, Timothy K., Padowski, Jeannie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438472/
https://www.ncbi.nlm.nih.gov/pubmed/28436395
http://dx.doi.org/10.3233/JPD-161040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438472/
https://www.ncbi.nlm.nih.gov/pubmed/28436395
http://dx.doi.org/10.3233/JPD-161040

Ejemplares similares